GeberJParraDBeckeyNKormanL. Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting. Pharmacotherapy2002;22 (6):738–47
2.
GoffDCGuLCantleyLKEnhancing the quality of care for patients with coronary heart disease: the design and baseline results of the Hastening the Effective Application of Research Through Technology (HEART) Trial. Am J Manag Care2002;8:1069–78
3.
CarterBZillichAElliotW. How pharmacists can assist physicians with controlling blood pressure. J Clin Hypertens2003;5 (1):31–7
4.
RothmanRMaloneRBryantBA randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. Am J Med.2005;118:276–84
5.
BozovichMRubinoCEdmundsJ. Effect of a clinical pharmacist-managed lipid clinic on achieving national cholesterol education program low-density lipoprotein goals. Pharmacotherapy2000;20:1375–83
6.
TsuyukiRJohnsonJTeoKA randomized trial of the effect of community pharmacist intervention on cholesterol risk management. Arch Intern Med.2002;162:1149–55
7.
GESICA InvestigatorsRandomised trial of telephone intervention on chronic heart failure: DIAL trial. BMJ2005;331 (7514):425
8.
FaulknerMWadibiaCLucasDHillemanD. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy2000;20 (4):410–6
9.
SimpsonSJohnsonJBiggsRTsuyukiR. Greater effect of enhanced pharmacist care on cholesterol management in patients with diabetes mellitus: a planned subgroup analysis of the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Pharmacotherapy2004;24 (3):389–94
10.
YamadaCJohnsonJRobertsonPLong-term impact of a community pharmacist intervention on cholesterol levels in patients at high risk for cardiovascular events: extended follow-up of the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). Pharmacotherapy2005;25 (1):110–5
11.
McPhersonRFrohlichJFodorGGenestJ. Canadian Cardiovascular Society position statement — recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol2006;22 (11):913–27
12.
Canadian Diabetes Association2003 Clinical practice guidelines for the prevention and management of diabetes in Canada — targets for glycemic control. Can J Diabetes2003;27:S18–20
13.
HemmelgarnBMcAlisterFGroverSThe 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part I — blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol2006;22:573–81
14.
KhanNMcAlisterFRabkinSThe 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part II — therapy. Can J Cardiol2006;22:583–593
